On March 27, 2024, Legend Biotech entered a manufacturing agreement with Novartis for the production of a CAR-T therapy, effective through December 31, 2029. This agreement involves a volume commitment and specific performance metrics for Novartis, ensuring supply for clinical and commercial needs.